In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

CancerVax, YM Bio and CIMAB in cancer deal

Executive Summary

Cancer therapeutics company CancerVax's Tarcanta and Tarcanta Ltd. subsidiaries have licensed from CIMAB SA (commercial branch of Cuba's Center of Molecular Immunology and YM BioSciences (cancer; has an existing relationship with YM) exclusive rights to complete clinical development on three oncology immunotherapeutics. CancerVax also gets rights to commercialize successful products from the deal in the US, Western Europe, Canada, Japan, Australia, New Zealand, and Mexico.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies